Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Amyloidosis × ixazomib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 20 Lymphoma 4 Recurrence 3 Hematologic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Amyloidosis 1 Advanced Non-hematologic Malignancies 1

Interventions

miridesap 3 Dexamethasone 2 venetoclax 1 ixazomib 1 birtamimab 1 belantamab mafodotin 1 Pharmaceutical Preparations 1 Lisaftoclax 1 GTP Cyclohydrolase 1 Drug Evaluation 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02924272 2025-03-12

Ixazomib Rollover Study

Takeda

Phase 2 Completed

32 enrolled 13 charts

LymphoidPlasma cell

Amyloidosis, Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡